What is IMUX's current stock price?

IMUX (Immunic, Inc.) is currently trading at $13.05 with a market cap of $128.8M.

What sector is Immunic, Inc. in?

Immunic, Inc. (IMUX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMUX a good stock to buy?

Analysts have a Buy consensus on IMUX with a price target of $14.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMUX Immunic, Inc.

Healthcare

$13.05+6.10%ClosedMarket Cap: $128.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.60

P/S

0.00

EV/EBITDA

0.52

DCF Value

$0.60

FCF Yield

-63.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-220.7%

ROA

-55.0%

ROIC

-72.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-32.6M	$—
Q4 null	$0.00	$-19.3M	$—
FY null	$0.00	$-97.2M	$—
Q3 null	$0.00	$-25.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$14.50

Target (Median)

$19.00

Target Range

$2.50 - $22.00

0 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

B. Riley SecuritiesBuy

2026-05-22

HC Wainwright & Co.Buy

2026-04-30

D. Boral CapitalHold

2026-04-15

HC Wainwright & Co.Buy

2026-03-02

D. Boral CapitalBuy

2026-02-13

Trading Activity

Insider Trades

View All

BONNEY MICHAEL Wdirector:

SellTue May 19

Panzara Michael A.officer: Chief Medical Officer

SellWed Apr 29

Panzara Michael A.officer

SellWed Apr 29

Congleton Jondirector:

SellTue Mar 31

Nagel Robert Thorvalddirector:

SellFri Feb 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.21

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Peers